These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20037443)

  • 1. [A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
    Egawa T; Ohashi M; Ito Y; Mihara K; Takahashi T; Hayashi S; Nagashima A
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2422-4. PubMed ID: 20037443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
    Kawashima H; Itoh A; Ohno E; Nakamura M; Miyahara R; Ohmiya N; Hara K; Kanamori A; Itoh T; Taki T; Hirai T; Hashimoto S; Takeda K; Goto H; Hirooka Y
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):677-83. PubMed ID: 21132496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.
    Kobayashi S; Ueno M; Ohkawa S; Andou T; Kameda R; Yamamoto N; Morinaga S
    Jpn J Clin Oncol; 2012 Sep; 42(9):800-6. PubMed ID: 22826349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
    Omori K; Wakabayashi K; Suematsu Y; Suda H; Hiratsuka M; Takahashi M; Saito H; Ishibashi Y; Morita A; Ito Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1582-4. PubMed ID: 26805103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
    Miyagawa K; Yata Y; Yamaoka N; Sagara Y
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1145-7. PubMed ID: 20567125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
    Nakai Y; Isayama H; Sasaki T; Sasahira N; Kogure H; Hirano K; Tsujino T; Ijichi H; Tateishi K; Tada M; Omata M; Koike K
    Jpn J Clin Oncol; 2010 Aug; 40(8):774-80. PubMed ID: 20462979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.
    Morizane C
    Jpn J Clin Oncol; 2007 Dec; 37(12):973. PubMed ID: 18211987
    [No Abstract]   [Full Text] [Related]  

  • 9. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
    Sudo K; Yamaguchi T; Nakamura K; Denda T; Hara T; Ishihara T; Yokosuka O
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):249-54. PubMed ID: 20352216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
    Kuji M; Yamamoto Y; Tani C; Kenno S; Kobayashi T
    Gan To Kagaku Ryoho; 2011 May; 38(5):853-5. PubMed ID: 21566453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study.
    Harano Y; Babazono A; Fujita T; Jiang P
    J Geriatr Oncol; 2019 May; 10(3):420-426. PubMed ID: 30236507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
    Takahara N; Isayama H; Nakai Y; Ishigami H; Satoi S; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Yamaguchi H; Tada M; Kitayama J; Watanabe T; Koike K
    Invest New Drugs; 2016 Oct; 34(5):636-42. PubMed ID: 27339809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
    Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
    Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
    Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
    Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
    Maeda A; Boku N; Fukutomi A; Kondo S; Kinoshita T; Nagino M; Uesaka K
    Jpn J Clin Oncol; 2008 Mar; 38(3):227-9. PubMed ID: 18272475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
    Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
    Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.